| |
Tolvaputan+carperitide group (n=51) |
Carperitide group (n=51) |
p value |
| Age(years) |
76.2±12.0 |
77.4±12.6 |
n.s. |
| Gender(male) |
27(52.9%) |
30(58.8%) |
n.s. |
| BMI |
21.0±4.3 |
21.8±4.0 |
n.s. |
| Smokers |
18(35.3%) |
17(33.3%) |
n.s. |
| Hypertension |
36(70.6%) |
44(86.3%) |
n.s. |
| Diabetes mellitus |
15(29.4%) |
18(35.3%) |
n.s. |
| Dyslipidemia |
15(29.4%) |
17(33.3%) |
n.s. |
| Cerebral infarction |
3(5.9%) |
4(7.8%) |
n.s. |
| Atrial fibrillation |
21(41.2%) |
17(33.3%) |
n.s. |
| Ischemic heart disease |
23(46.0%) |
22(43.1%) |
n.s. |
| History of heart failure |
33(64.7%) |
26(51.0%) |
n.s. |
| Etiology |
| Arrhythmia |
9(17.7%) |
15(29.4%) |
n.s |
| Ischemic heart disease |
15(29.4%) |
21(38.9%) |
|
| Valvular disease |
6(11.8%) |
3(5.9%) |
|
| Dilated cardiomyopathy |
12(23.5%) |
7(13.7%) |
|
| Other |
9(17.7%) |
5(9.8%) |
|
| Concomitant medication |
| ACE inhibitors or ARBs |
45(88.2%) |
36(70.6%) |
n.s. |
| β-blockers |
37(72.6%) |
33(64.1%) |
n.s. |
| Ca-blockers |
11(21.6%) |
12(23.5%) |
n.s. |
| Loop diuretics |
43(84.3%) |
39(76.5%) |
n.s. |
| Spironolactone |
29(56.9%) |
11(21.6%) |
<0.01 |
| NYHAII |
2(3.9%) |
2(3.9%) |
n.s. |
| III |
20(39.2%) |
19(37.3%) |
n.s. |
| IV |
29(56.9%) |
30(58.8%) |
n.s. |
| Clinical scenario1 |
20(39.2%) |
20(39.2%) |
n.s. |
| 2 |
20(39.2%) |
27(52.9%) |
|
| 3 |
8(15.7%) |
4(7.8%) |
|
| 5 |
3(5.9%) |
0 |
|
| Systolic blood pressure(mmHg) |
141.0±39.0 |
136.2±27.8 |
n.s. |
| Diastolic blood pressure(mmHg) |
81.7±26.2 |
78.8±21.4 |
n.s. |
| Heart rate(/min) |
91.4±25.8 |
83.8±21.1 |
n.s. |
| Serum creatinine(mg/dl) |
1.5±0.8 |
1.3±0.6 |
n.s. |
| Estimated GFR (mL/min/1.73m2) |
38.8±20.2 |
43.2±21.7 |
n.s. |
| Serum sodium (mEq/L) |
138.6±5.2 |
138.2±3.8 |
n.s. |
| Serum potassium (mEq/L) |
4.2±0.6 |
4.1±0.5 |
n.s. |
| NT-pro BNP (pg/ml) |
17486.8±25689.4 |
7774.0±8291.5 |
0.01 |
| Echocardiography |
| left atrium volume index(ml/m2) |
47.7±22.5 |
36.4±14.9 |
<0.01 |
| Left ventricular end diastolic diameter(mm) |
52.8±9.3 |
50.6±9.8 |
n.s. |
| Left ventricular end systolic diameter(mm) |
42.4±11.5 |
39.4±10.7 |
n.s. |
| Left ventricular end diastolic volume(ml) |
128.8±74.9 |
105.7±49.5 |
n.s. |
| Left ventricular end systolic volume(ml) |
83.4±67.3 |
63.7±42.8 |
n.s. |
| Left ventricular ejection fraction(%) |
40.3±16.7 |
44.5±14.5 |
n.s. |
| Medication |
| Dose of tolvaptan(mg/day) |
12.7±3.5 |
|
|
| Duration of administration[day](IQR) |
3(3-8) |
|
|
| Dose of carperitide(μg/kg/min) |
0.024±0.013 |
0.037±0.023 |
<0.01 |
| Total dose of carperitide(μg) |
1660±1310 |
2470±2300 |
0.03 |
| Duration of administration[day](IQR) |
8.0(5-14) |
7.0(5-10) |
n.s. |
| Dose of intravenous furosemide for 48h(mg) |
11.4±16.6 |
29.2±30.6 |
<0.001 |
| Nitroglycerin |
13(25.5%) |
9(17.7%) |
n.s. |
| Cardiac stimulant |
15(29.4%) |
8(15.7%) |
n.s. |
| Non-invasive positive-pressure ventilation |
16(31.4%) |
17(33.3%) |
n.s. |
| Duration of hospitalization (day) |
23.3±25.1 |
24.7±24.2 |
n.s. |
